Myriad Genetics, Inc.
Biopharmaceutical company announces patent on amyloid lowering drugs
Published in Drug Law Weekly, July 26th, 2005
Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.
Amyloid beta 42 is a neurotoxic peptide that is the primary constituent of senile plaques that accumulate in the brains of patients with Alzheimer disease. It is thought to be the key initiator of Alzheimer disease since this peptide has the greatest tendency to aggregate, cause neuronal damage...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2005-07-26)
More Articles from Drug Law Weekly
- Chemokine Therapeutics Corp.
U.S. patent allowed for novel cancer drug in clinical development - Frost & Sullivan
Consultancy releases study on pharma industry - Generex Biotechnology Corp.
Drug-delivery company gets Mexican patent - Hacettepe University, Ankara
N-acetylcysteine treatment has no prophylactic use - Medtronic, Inc.
Technology company purchases land for new headquarters, launches online resource - National Prostate Cancer Coalition
ED drug amendment passage puts lives at risk, says prostate cancer organization - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
